Phase II study of gemcitabine in patients with advanced pancreatic cancer, Br. J. Cancer, vol.73, pp.101-105, 1996. ,
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer, Lung Cancer, vol.42, pp.97-102, 2003. ,
Gemcitabine plus paclitaxel in breast cancer, Semin. Oncol, vol.32, issue.4, pp.14-21, 2005. ,
Gemcitabine and Carboplatin in Second-Line Ovarian Cancer, Seminars in Oncology, vol.32, issue.4, pp.4-8, 2005. ,
DOI : 10.1053/j.seminoncol.2005.06.023
Equilibrativesensitive nucleoside transporter and its role in gemcitabine sensitivity, Cancer Res, vol.60, pp.6075-6079, 2000. ,
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer, Gastroenterology, vol.136, issue.1, pp.187-195, 2009. ,
DOI : 10.1053/j.gastro.2008.09.067
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine, Oncogene, vol.23, issue.8, pp.1539-1548, 2004. ,
DOI : 10.1038/sj.onc.1207272
Multimeric, Multifunctional Derivatives of Poly(ethylene glycol), Polymers, vol.3, issue.4, pp.1076-1090, 2011. ,
DOI : 10.3390/polym3031076
A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration, Journal of Controlled Release, vol.86, issue.1, pp.93-100, 2003. ,
DOI : 10.1016/S0168-3659(02)00323-1
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines, Biochem. Pharmacol, vol.67, pp.503-511, 2004. ,
Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment, Proc. Natl. Acad. Sci. U.S.A, vol.91, pp.8403-8407, 1994. ,
Advanced pancreatic carcinoma: current treatment and future challenges, Nature Reviews Clinical Oncology, vol.61, issue.3, pp.163-172, 2010. ,
DOI : 10.1038/nrclinonc.2009.236
Gemcitabine HCL) for injection, 2005. ,
Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors, Journal of Clinical Oncology, vol.22, issue.12, pp.2445-2451, 2004. ,
DOI : 10.1200/JCO.2004.10.142
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine., Journal of Clinical Oncology, vol.9, issue.3, pp.491-498, 1991. ,
DOI : 10.1200/JCO.1991.9.3.491
Nucleoside and nucleobase transport systems of mammalian cells, Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, vol.1286, issue.3, pp.153-181, 1996. ,
DOI : 10.1016/S0304-4157(96)00008-1
The Role of Human Nucleoside Transporters in Uptake of 3'-Deoxy-3'-fluorothymidine, Molecular Pharmacology, vol.74, issue.5, pp.1372-1380, 2008. ,
DOI : 10.1124/mol.108.048900
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?, British Journal of Cancer, vol.24, issue.2, pp.145-151, 2007. ,
DOI : 10.1097/00008571-200301000-00005
Effect of its deaminated metabolite, 2???,2???-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells, Biochemical Pharmacology, vol.81, issue.7, pp.950-956, 2011. ,
DOI : 10.1016/j.bcp.2011.01.016
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells, Oncol. Rep, vol.17, pp.1201-1205, 2007. ,
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine, Cancer Res, vol.66, pp.3928-3935, 2006. ,
Preclinical characteristics of gemcitabine, Anti-Cancer Drugs, vol.6, issue.Supplement 6, pp.7-13, 1995. ,
DOI : 10.1097/00001813-199512006-00002
Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs, pp.176-183, 1999. ,
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation, Cancer Res, vol.52, pp.533-539, 1992. ,
Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?, Fundamental & Clinical Pharmacology, vol.7, issue.Pt B, pp.172-185, 2011. ,
DOI : 10.1111/j.1472-8206.2010.00823.x
Determinants of resistance to 2???,2???-difluorodeoxycytidine (gemcitabine), Drug Resistance Updates, vol.5, issue.1, pp.19-33, 2002. ,
DOI : 10.1016/S1368-7646(02)00002-X
Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer, Pancreas, vol.39, issue.8, pp.1284-1292, 2010. ,
DOI : 10.1097/MPA.0b013e3181dec17d
2???,2???-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines, Biochemical Pharmacology, vol.46, issue.4, pp.762-766, 1993. ,
DOI : 10.1016/0006-2952(93)90566-F
The Role of Membrane Transporters in Cellular Resistance to Anticancer Nucleoside Drugs, Cancer Treat. Res, vol.112, pp.27-47, 2002. ,
DOI : 10.1007/978-1-4615-1173-1_2
Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma, Clinical Cancer Research, vol.15, issue.8, pp.2913-2919, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2080
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC), Curr. Cancer Drug Targets, vol.11, pp.123-129, 2011. ,
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival, Clin. Cancer Res, vol.12, pp.2492-2497, 2006. ,
Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential, Clinical and Experimental Metastasis, vol.16, issue.1, pp.43-49, 1998. ,
DOI : 10.1023/A:1006559901771
Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines, Journal of Nucleic Acids, vol.51, issue.22, p.597098, 2010. ,
DOI : 10.1158/0008-5472.CAN-05-4462
Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy, Neoplasia, vol.12, issue.10, pp.807-817, 2010. ,
DOI : 10.1593/neo.10458
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines, European Journal of Cancer, vol.35, issue.5, pp.796-807, 1999. ,
DOI : 10.1016/S0959-8049(98)00425-0
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR-upregulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase, Cancer Res, vol.69, pp.4567-4572, 2009. ,
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients, Ann. Surg, vol.252, pp.499-505, 2010. ,
Preclinical, pharmacologic, and phase I studies of gemcitabine, Semin. Oncol, vol.24, issue.2, pp.7-9, 1997. ,
Covalent Conjugation of Poly(Ethylene Glycol) to Proteins and Peptides: Strategies and Methods, Methods Mol. Biol, vol.751, pp.95-129, 2011. ,
DOI : 10.1007/978-1-61779-151-2_8
State of the art in PEGylation: The great versatility achieved after forty years of research, Journal of Controlled Release, vol.161, issue.2, pp.461-472, 2012. ,
DOI : 10.1016/j.jconrel.2011.10.037
PEG conjugates in clinical development or use as anticancer agents: An overview, Advanced Drug Delivery Reviews, vol.61, issue.13, pp.61-1177, 2009. ,
DOI : 10.1016/j.addr.2009.02.010
Polyethylene glycol (peg) as a key component of long-circulating delivery systems for therapy and imaging, Pharm. Sci. Dissert, pp.1-107, 2008. ,
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)???protein conjugates, Advanced Drug Delivery Reviews, vol.55, issue.10, pp.1261-1277, 2003. ,
DOI : 10.1016/S0169-409X(03)00108-X
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, Journal of Controlled Release, vol.65, issue.1-2, pp.271-284, 2000. ,
DOI : 10.1016/S0168-3659(99)00248-5
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity, Toxicology, vol.216, issue.2-3, pp.106-121, 2005. ,
DOI : 10.1016/j.tox.2005.07.023
Nano-Sized Assemblies of a PEG-Docetaxel Conjugate as a Formulation Strategy for Docetaxel, Journal of Pharmaceutical Sciences, vol.97, issue.8, pp.3274-3290, 2008. ,
DOI : 10.1002/jps.21245
Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug, Anti-Cancer Drugs, vol.7, issue.6, pp.642-648, 1996. ,
DOI : 10.1097/00001813-199608000-00004
Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer, Biomaterials, vol.31, issue.35, pp.9340-9356, 2010. ,
DOI : 10.1016/j.biomaterials.2010.08.010
Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy, Molecular Cancer Therapeutics, vol.9, issue.6, pp.1903-1912 ,
DOI : 10.1158/1535-7163.MCT-09-0899
Endocytic mechanisms for targeted drug delivery???, Advanced Drug Delivery Reviews, vol.59, issue.8 ,
DOI : 10.1016/j.addr.2007.06.008
Antitumoral activity of PEG???gemcitabine prodrugs targeted by folic acid, Journal of Controlled Release, vol.127, issue.3, pp.239-248, 2008. ,
DOI : 10.1016/j.jconrel.2008.02.002
Functional folate receptor alpha is elevated in the blood of ovarian cancer patients Expression status of folate receptor alpha is significantly correlated with prognosis in non-smallcell lung cancers, PLoS ONE Ann. Surg. Oncol, vol.4, issue.15, pp.6292-55, 2008. ,
Folate receptor overexpression is associated with poor outcome in breast cancer, Int. J. Cancer, vol.121, pp.938-942, 2007. ,
Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells, Journal of Controlled Release, vol.146, issue.1, pp.76-83, 2010. ,
DOI : 10.1016/j.jconrel.2010.04.028
Folic Acid-Conjugated Chitosan Nanoparticles Enhanced Protoporphyrin IX Accumulation in Colorectal Cancer Cells, Bioconjugate Chemistry, vol.21, issue.4, pp.679-689, 2010. ,
DOI : 10.1021/bc9004798
Magnetic nanocarriers of doxorubicin coated with poly(ethylene glycol) and folic acid: relation between coating structure, surface properties, colloidal stability and cancer cell targeting, Langmuir, vol.28, pp.1496-1505, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01387921
PEG???Ara-C conjugates for controlled release, European Journal of Medicinal Chemistry, vol.39, issue.2, pp.123-133, 2004. ,
DOI : 10.1016/j.ejmech.2003.10.005
Intracellular Delivery of Nanometric DNA Particles via the Folate Receptor, Bioconjugate Chemistry, vol.13, issue.4, pp.831-839, 2002. ,
DOI : 10.1021/bc0255182
Effect of pegylation on pharmaceuticals, Nature Reviews Drug Discovery, vol.18, issue.3, pp.214-221, 2003. ,
DOI : 10.1038/nrd1033
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine, J. Med. Chem, vol.52, pp.6958-6961, 2009. ,
Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.17, issue.18, pp.6071-6082, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0353
Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology, Molecules, vol.14, issue.1, pp.540-554, 2009. ,
DOI : 10.3390/molecules14010540
Squalene and its potential clinical uses, Altern. Med. Rev, vol.4, issue.66, pp.29-36, 1999. ,
Squalene, Olive Oil, and Cancer Risk: Review and Hypothesis, Annals of the New York Academy of Sciences, vol.84, issue.4, pp.1101-1103, 1997. ,
DOI : 10.1007/BF01990031
Squalenoyl nanomedicines as potential therapeutics, Nano Lett, vol.6, pp.2544-2548, 2006. ,
Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2012. ,
DOI : 10.1016/j.jconrel.2011.07.038
Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug, Clinical Cancer Research, vol.10, issue.16, pp.5614-5621, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0506
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines, Cancer Res, pp.61-7217, 2001. ,
A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types, J. Control. Release, vol.124, pp.20-27, 2007. ,
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer, Nanomedicine: Nanotechnology, Biology and Medicine, vol.7, issue.6, pp.841-849, 2011. ,
DOI : 10.1016/j.nano.2011.02.012
Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation, Nanoscale, vol.2, pp.1521-1526, 2010. ,
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics, ACS Nano, vol.5, pp.1513-1521, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00589109
Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: An original drug delivery pathway, J. Control. Release, vol.147, pp.163-170, 2010. ,
Cathepsin B and its role(s) in cancer progression, Biochemical Society Symposium, vol.70, pp.263-276, 2003. ,
DOI : 10.1042/bss0700263
Cathepsin L increases invasion and migration of B16 melanoma, Cancer Cell International, vol.7, issue.1, 2007. ,
DOI : 10.1186/1475-2867-7-8
antitumor activity, Expert Opinion on Drug Delivery, vol.30, issue.2, pp.1609-1629, 2011. ,
DOI : 10.1111/j.1464-410X.2010.09496.x
Novel Nanoassemblies Composed of Squalenoyl???Paclitaxel Derivatives: Synthesis, Characterization, and Biological Evaluation, Bioconjugate Chemistry, vol.21, issue.7, pp.1349-1361, 2011. ,
DOI : 10.1021/bc100154g
Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model, Clin. Exp. Metastasis, vol.26, pp.981-992, 2009. ,
EGFR Targeted PLGA Nanoparticles Using Gemcitabine for Treatment of Pancreatic Cancer, Journal of Biomedical Nanotechnology, vol.7, issue.1, pp.137-138, 2011. ,
DOI : 10.1166/jbn.2011.1238
Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment, European Journal of Cancer, vol.47, issue.12, pp.1873-1882, 2011. ,
DOI : 10.1016/j.ejca.2011.03.018
Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation, Biomedical Microdevices, vol.356, issue.5, pp.799-807, 2011. ,
DOI : 10.1007/s10544-011-9550-6
Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules, Int. J. Pharm, vol.344, pp.71-77, 2007. ,
Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy, Nanomedicine: Nanotechnology, Biology and Medicine, vol.7, issue.6, pp.859-870, 2011. ,
DOI : 10.1016/j.nano.2011.03.009
From Conventional to Stealth Liposomes: a New Frontier in Cancer Chemotherapy, Journal of Chemotherapy, vol.2000, issue.sup4, pp.237-249, 2003. ,
DOI : 10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H
PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery, Current Drug Metabolism, vol.13, issue.1, pp.105-109, 2012. ,
DOI : 10.2174/138920012798356934
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, Journal of Controlled Release, vol.100, issue.3, pp.331-346, 2004. ,
DOI : 10.1016/j.jconrel.2004.09.001
Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-.BETA.-D-arabinofuranosylcytosine prodrug-bearing liposomes., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.36, issue.9, pp.3574-3583, 1988. ,
DOI : 10.1248/cpb.36.3574
Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, Anticancer Res, vol.27, pp.195-199, 2007. ,
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles, International Journal of Pharmaceutics, vol.409, issue.1-2, pp.278-288, 2011. ,
DOI : 10.1016/j.ijpharm.2011.02.037
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1, Journal of Controlled Release, vol.157, issue.1, pp.132-140, 2012. ,
DOI : 10.1016/j.jconrel.2011.08.004
EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity, J. Control. Release, vol.157, pp.287-296, 2012. ,
Sensitizing of gemcitabine-resistant human leukemia cells by stearoyl gemcitabine nanoparticles. Nanomedecien (Lond, pp.1491-1492, 2011. ,
EGFR and cancer prognosis, European Journal of Cancer, vol.37, pp.9-15, 2001. ,
DOI : 10.1016/S0959-8049(01)00231-3
EGFR-Targeted Hybrid Plasmonic Magnetic Nanoparticles Synergistically Induce Autophagy and Apoptosis in Non-Small Cell Lung Cancer Cells, PLoS ONE, vol.4, issue.11, p.25507, 2011. ,
DOI : 10.1371/journal.pone.0025507.s005
EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma, Biomaterials, vol.33, issue.1, pp.270-282, 2012. ,
DOI : 10.1016/j.biomaterials.2011.09.035
In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain, J. Control. Release, vol.158, pp.63-71, 2011. ,
Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer, Current Medicinal Chemistry, vol.16, issue.35, pp.4632-4643, 2009. ,
DOI : 10.2174/092986709789878229
Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models, Cancer Res, vol.59, pp.2944-2949, 1999. ,
Intravenous administration of CP-4055 (ELACYT???) in patients with solid tumours. A phase I study, Acta Oncologica, vol.28, issue.1, pp.137-145, 2009. ,
DOI : 10.1007/BF00321053
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy, Cancer Chemotherapy and Pharmacology, vol.92, issue.Suppl 1, pp.1347-1353, 2011. ,
DOI : 10.1007/s00280-011-1735-4
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126, Invest. New Drugs, 2011. ,
CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines, British Journal of Haematology, vol.253, issue.2, pp.273-275, 2009. ,
DOI : 10.1111/j.1365-2141.2008.07467.x
The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues, Nucleosides, Nucleotides and Nucleic Acids, vol.28, issue.4-6, pp.386-393, 2010. ,
DOI : 10.1200/JCO.2008.20.1111
Safety of pulmonary administration of gemcitabine in rats, J. Aerosol Med, vol.18, pp.198-206, 2005. ,
Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel, Int. J. Oncol, vol.36, issue.112, pp.285-294, 2010. ,
Ahmad, I. Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002) ,
Deficiency of Cardiolipin Synthase Causes Abnormal Mitochondrial Function and Morphology in Germ Cells of Caenorhabditis elegans, Journal of Biological Chemistry, vol.287, issue.7, pp.4590-4601, 2012. ,
DOI : 10.1074/jbc.M111.314823
A novel gemcitabine-cardiolipin conjugate induced cytotoxicity in cancer cells through an equilibrative nucleoside transporter-independent pathway. AACR Meeting Abstracts, 2005. ,
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate, Anticancer Drugs, vol.17, pp.53-61, 2006. ,
Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs, International Journal of Pharmaceutics, vol.395, issue.1-2, pp.281-289, 2010. ,
DOI : 10.1016/j.ijpharm.2010.05.028
Prodrugs of Ara-CMP and Ara-AMP with a S-acyl-2-thioethyl (SATE) biolabile phosphate protecting group: synthesis and biological evaluation, Nucleosides Nucleotides, vol.18, pp.971-972, 1999. ,
Synthesis and Biological Studies of Novel Nucleoside Phosphoramidate Prodrugs, Journal of Medicinal Chemistry, vol.44, issue.25, pp.4475-4480, 2001. ,
DOI : 10.1021/jm010337r
Gemcitabine phosphoester prodrugs as anticancer agents, 2009. ,
The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5- fluoro-2?-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes, Biochem. Pharmacol, vol.82, pp.441-452, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00721644
Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus, Bioorg. Med. Chem. Lett, vol.20, pp.4850-4854, 2010. ,
INX-08189, a phosphoramidate prodrug of 6-O-methyl-2?-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties ,
Synthesis and Biological Evaluation of a Cytarabine Phosphoramidate Prodrug, Molecular Pharmaceutics, vol.1, issue.2, pp.112-116, 2004. ,
DOI : 10.1021/mp034019v
Phosphoramidates of 2?-?-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism, Bioorg. Med. Chem, vol.18, pp.2439-2446, 2010. ,
Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug, Journal of Medicinal Chemistry, vol.50, issue.15, pp.3743-3746, 2007. ,
DOI : 10.1021/jm070269u
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J. Clin. Oncol, vol.15, pp.2403-2413, 1997. ,